A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study compares the efficacy and safety of modified release prednisone versus immediate release prednisone in patients suffering from polymyalgia rheumatica.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

NCT00650078

Rheumatoid Arthritis

COMPLETED PHASE3

Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis

NCT03368235

Rheumatoid Arthritis

COMPLETED PHASE2

Delayed Release Prednisone in PMR

NCT02702778

Polymyalgia Rheumatica

TERMINATED PHASE2

Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis

NCT00241982

Rheumatoid Arthritis

COMPLETED PHASE2

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

NCT02908217

Polymyalgia Rheumatica

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consists of a screening phase, followed by a 4 week double-blind phase. During the double-blind phase, the patients will be randomised in a 1:1 ratio to either Lodotra® or immediate release prednisone (prednisone IR) plus respective placebo.

After completion of the double-blind phase, patients will be re-randomised in a 1:1 ratio to open-label Lodotra® or prednisone IR for 48 weeks. During the open-label phase, the dose of study medication will be tapered based on titration criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polymyalgia Rheumatica

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lodotra®

Lodotra, starting dose of 15mg administered in the evening

Group Type EXPERIMENTAL

Lodotra®

Intervention Type DRUG

Lodotra, starting dose of 15mg administered in the evening

Prednisone IR

Prednisone IR 15mg daily start dose (immediate release) administered in the morning

Group Type ACTIVE_COMPARATOR

Prednisone IR (immediate release)

Intervention Type DRUG

Prednisone IR 15mg daily start dose (immediate release) administered in the morning,

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lodotra®

Lodotra, starting dose of 15mg administered in the evening

Intervention Type DRUG

Prednisone IR (immediate release)

Prednisone IR 15mg daily start dose (immediate release) administered in the morning,

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Modified release prednisone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females, 50 years of age or older who provided written informed consent.
2. Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner).
3. Subjects newly diagnosed with polymyalgia rheumatica and previously untreated with glucocorticoids for PMR. The diagnosis of polymyalgia rheumatica must be confirmed by all of the following criteria:

* New onset bilateral shoulder pain or new onset bilateral shoulder and hip girdle pain.
* PMR VAS score over the last 24 hours before the Screening Visit ≥ 50 (on a 0 - 100 scale).
* Morning stiffness duration of ≥ 45 min on the day before the Screening Visit.
* Acute phase response shown by elevated C-reactive protein (CRP; ≥ 2 times ULN).
4. Subjects willing and able to participate in all aspects of the study and comply with the use of study medication.

Exclusion Criteria

1. Females who are pregnant (positive β-hCG test) or lactating.
2. Subjects with any contraindication/history of hypersensitivity to predniso(lo)ne or other ingredients.
3. Significant renal impairment (serume creatinine \> 150 µmol/L).
4. Significant hepatic impairment (ALT, AST and GGT \> 2.5 ULN).
5. Subjects suffering from another disease which requires glucocorticosteroid treatment. Topical glucocorticosteroids, e.g. intra-nasal or inhaled glucocorticosteroids are allowed but should be kept at a stable dose throughout the study.
6. Continued use of systemic glucocorticoids within 4 weeks prior to the Screening Visit.
7. Joint injections with glucocorticoids within 6 weeks prior to the Screening Visit.
8. Subjects who require treatment with non-permitted concomitant therapies.
9. Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal or psychiatric disease at the time of screening, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the subject at risk upon exposure to the study medication or that may confound the analysis and/or interpretation of the study results.
10. Active alcohol or drug abuse.
11. Subjects suffering from giant cell arteritis, late onset rheumatoid arthritis or other inflammatory rheumatoid diseases.
12. Subjects suffering from drug-induced myalgia.
13. Subjects suffering from fibromyalgia
14. Subjects suffering from systemic lupus erythemathosus.
15. Subjects suffering from neurological conditions, e.g. Parkinson's disease.
16. Subjects suffering from active cancer.
17. Subjects suffering from an active infection.
18. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days prior to the Screening Visit.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No